KR20050044812A - Ｌｉｐｇ의 발현을 저하시키고 고밀도 지단백질(ｈｄｌ)콜레스테롤 및 아포지단백질 ａｉ의 수준을 증가시키는조성물 - Google Patents

Ｌｉｐｇ의 발현을 저하시키고 고밀도 지단백질(ｈｄｌ)콜레스테롤 및 아포지단백질 ａｉ의 수준을 증가시키는조성물 Download PDF

Info

Publication number
KR20050044812A
KR20050044812A KR1020057005114A KR20057005114A KR20050044812A KR 20050044812 A KR20050044812 A KR 20050044812A KR 1020057005114 A KR1020057005114 A KR 1020057005114A KR 20057005114 A KR20057005114 A KR 20057005114A KR 20050044812 A KR20050044812 A KR 20050044812A
Authority
KR
South Korea
Prior art keywords
lipg
leu
gly
ser
val
Prior art date
Application number
KR1020057005114A
Other languages
English (en)
Korean (ko)
Inventor
마이클 제이
케빈 제이 린치
딜립 브이 아민
킴-안 티 도안
돈 마캐디어
시릴 마우게에이스
다니엘 제이 레이더
존 에이 크레윅
빅토리아 제이 사우쓰
Original Assignee
아벤티스 파마슈티칼스 인크.
더 트러스티즈 오브 더 유니버서티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by 아벤티스 파마슈티칼스 인크., 더 트러스티즈 오브 더 유니버서티 오브 펜실베니아 filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20050044812A publication Critical patent/KR20050044812A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020057005114A 1999-03-26 2000-03-24 Ｌｉｐｇ의 발현을 저하시키고 고밀도 지단백질(ｈｄｌ)콜레스테롤 및 아포지단백질 ａｉ의 수준을 증가시키는조성물 KR20050044812A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US09/277,401 1999-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012300A Division KR100887164B1 (ko) 1999-03-26 2000-03-24 Ｌｉｐｇ 폴리펩타이드의 활성을 증가시키고 초저밀도 지단백질(ｖｌｄｌ) 콜레스테롤 및 저밀도 지단백질(ｌｄｌ) 콜레스테롤의 수준을 저하시키는 조성물 및 이를 위해 유용한 화합물을 동정하는 방법

Publications (1)

Publication Number Publication Date
KR20050044812A true KR20050044812A (ko) 2005-05-12

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057005114A KR20050044812A (ko) 1999-03-26 2000-03-24 Ｌｉｐｇ의 발현을 저하시키고 고밀도 지단백질(ｈｄｌ)콜레스테롤 및 아포지단백질 ａｉ의 수준을 증가시키는조성물
KR1020017012300A KR100887164B1 (ko) 1999-03-26 2000-03-24 Ｌｉｐｇ 폴리펩타이드의 활성을 증가시키고 초저밀도 지단백질(ｖｌｄｌ) 콜레스테롤 및 저밀도 지단백질(ｌｄｌ) 콜레스테롤의 수준을 저하시키는 조성물 및 이를 위해 유용한 화합물을 동정하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020017012300A KR100887164B1 (ko) 1999-03-26 2000-03-24 Ｌｉｐｇ 폴리펩타이드의 활성을 증가시키고 초저밀도 지단백질(ｖｌｄｌ) 콜레스테롤 및 저밀도 지단백질(ｌｄｌ) 콜레스테롤의 수준을 저하시키는 조성물 및 이를 위해 유용한 화합물을 동정하는 방법

Country Status (13)

Country Link
EP (1) EP1171078A4 (fr)
JP (1) JP2002540127A (fr)
KR (2) KR20050044812A (fr)
AU (1) AU776684B2 (fr)
BR (1) BR0009333A (fr)
CA (1) CA2363486C (fr)
HK (1) HK1043309A1 (fr)
IL (2) IL145526A0 (fr)
MX (1) MXPA01009727A (fr)
NO (2) NO331779B1 (fr)
NZ (2) NZ531180A (fr)
WO (1) WO2000057837A2 (fr)
ZA (1) ZA200107598B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
EP1976567B1 (fr) 2005-12-28 2020-05-13 The Scripps Research Institute Utilisation de transcrits d'arn antisens et non codants naturels comme cibles de médicaments
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
DK2396038T3 (en) 2009-02-12 2016-02-01 Curna Inc TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
EP2408919B1 (fr) 2009-03-16 2017-10-18 CuRNA, Inc. Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
EP2408920B1 (fr) 2009-03-17 2017-03-08 CuRNA, Inc. Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1
WO2010129799A2 (fr) 2009-05-06 2010-11-11 Curna, Inc. Traitement de maladies associées aux gènes du métabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gène du métabolisme et du transport des lipides
WO2010129746A2 (fr) 2009-05-06 2010-11-11 Curna, Inc. Traitement de maladies liées à la tristétraproline (ttp) par l'inhibition d'un transcrit antisens naturel de ttp
WO2010129861A2 (fr) 2009-05-08 2010-11-11 Curna, Inc. Traitement de maladies liées à la famille de la dystrophine par inhibition du produit antisens naturel de transcription vers la famille de la dmd
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
WO2010135695A2 (fr) 2009-05-22 2010-11-25 Curna, Inc. Traitement des maladies liées au facteur de transcription e3 (tfe3) et au substrat récepteur d'insuline 2 (irs2) par inhibition du transcript antisens naturel du tfe3
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
EP2443237B1 (fr) 2009-06-16 2017-02-22 CuRNA, Inc. Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène
WO2010151671A2 (fr) 2009-06-24 2010-12-29 Curna, Inc. Traitement de maladies associées au récepteur de facteur nécrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2
EP2446037B1 (fr) 2009-06-26 2016-04-20 CuRNA, Inc. Traitement de maladies associées aux gènes liés au syndrome de down par inhibition des gènes liés au syndrome de down médiée par le produit de transcription antisens naturel
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011017516A2 (fr) 2009-08-05 2011-02-10 Curna, Inc. Traitement de maladies liées à un gène de l’insuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins)
CA2770104C (fr) 2009-08-11 2019-03-19 Opko Curna, Llc Traitement de maladies associees a l'adiponectine (adipoq) par inhibition du produit de transcription anti-sens naturel d'une adiponectine (adipoq)
JP5943836B2 (ja) 2009-08-21 2016-07-05 カッパーアールエヌエー，インコーポレイテッド ‘ｈｓｐ７０相互作用タンパク質ｃ末端’（ｃｈｉｐ）に対する天然アンチセンス転写産物の阻害によるｃｈｉｐ関連疾患の治療
CA2771172C (fr) 2009-08-25 2021-11-30 Opko Curna, Llc Traitement de maladies associees a la proteine d'activation de gtpase contenant un motif iq (iqgap), par inhibition d'un transcrit antisens naturel de iqgap
NO2480669T3 (fr) 2009-09-25 2018-04-07
JP6025567B2 (ja) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
EP2516648B1 (fr) 2009-12-23 2017-11-08 CuRNA, Inc. Traitement de maladies associées au facteur de croissance des hépatocytes (hgf) par inhibition de la transcription antisens naturelle en hgf
CA2785173A1 (fr) 2009-12-29 2011-07-28 Curna, Inc. Traitement de maladies liees au facteur respiratoire nucleaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1
KR101853508B1 (ko) 2009-12-29 2018-06-20 큐알엔에이, 인크. 종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
CN102791862B (zh) 2009-12-31 2017-04-05 库尔纳公司 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
NO2521784T3 (fr) 2010-01-04 2018-05-05
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
EP2539452B1 (fr) 2010-02-22 2016-07-27 CuRNA, Inc. Traitement de maladies liées à la pyrroline-5-carboxylate réductase 1 (pycr1) par inhibition du produit de transcription antisens naturel de pycr1
KR101877065B1 (ko) 2010-04-02 2018-07-10 큐알엔에이, 인크. 집락 자극 인자 3 (ｃｓｆ3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (ｃｓｆ3) 관련된 질환의 치료
RU2610661C2 (ru) 2010-04-09 2017-02-14 Курна, Инк. Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
JP2013525483A (ja) 2010-05-03 2013-06-20 カッパーアールエヌエー，インコーポレイテッド サーチュイン（ｓｉｒｔ）に対する天然アンチセンス転写物の阻害によるサーチュイン（ｓｉｒｔ）関連疾患の治療
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
WO2011150007A2 (fr) 2010-05-26 2011-12-01 Opko Curna Llc Traitement de maladies liées à la méthionine sulfoxide réductase a (msra) par inhibition de produit de transcription antisens naturel de msra
RU2588654C2 (ru) 2010-06-23 2016-07-10 Курна, Инк. Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna
EP2593547B1 (fr) 2010-07-14 2017-11-15 CuRNA, Inc. Traitement de maladies liées à « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg
CN103210086B (zh) 2010-10-06 2017-06-09 库尔纳公司 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
CN103180445B (zh) 2010-10-22 2018-02-16 库尔纳公司 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
WO2012068340A2 (fr) 2010-11-18 2012-05-24 Opko Curna Llc Compositions d'antagonat et leurs méthodes d'utilisation
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
CN103620036B (zh) 2011-06-09 2016-12-21 库尔纳公司 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
CN103874486A (zh) 2011-09-06 2014-06-18 库尔纳公司 用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
JP6362268B2 (ja) 2012-11-05 2018-07-25 塩野義製薬株式会社 Ｅｌ活性が関連する疾患の治療または予防効果を有する医薬の薬効評価方法及びｅｌ活性阻害物質のスクリーニング方法
BR112015022009A2 (pt) 2013-03-14 2017-08-29 Shionogi & Co Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular
TWI688575B (zh) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
WO2022165313A1 (fr) 2021-02-01 2022-08-04 Regenxbio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales
JPWO2023008337A1 (fr) * 2021-07-26 2023-02-02

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679525B2 (en) * 1992-12-04 1997-07-03 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
DE69732789T2 (de) * 1996-12-06 2005-08-11 Aventis Pharmaceuticals Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
ZA200107598B (en) 2003-05-28
NO331779B1 (no) 2012-03-26
HK1043309A1 (zh) 2002-09-13
NZ531180A (en) 2005-06-24
CA2363486A1 (fr) 2000-10-05
CA2363486C (fr) 2012-12-18
KR20020029651A (ko) 2002-04-19
MXPA01009727A (es) 2002-07-22
NO20014657L (no) 2001-11-21
EP1171078A4 (fr) 2002-11-06
BR0009333A (pt) 2002-01-08
IL145526A (en) 2010-11-30
NO20014657D0 (no) 2001-09-25
IL145526A0 (en) 2002-06-30
NO20100214L (no) 2001-11-21
NZ514350A (en) 2004-12-24
KR100887164B1 (ko) 2009-03-10
WO2000057837A2 (fr) 2000-10-05
AU3918700A (en) 2000-10-16
WO2000057837A8 (fr) 2001-09-27
NO331784B1 (no) 2012-03-26
WO2000057837A3 (fr) 2001-01-25
EP1171078A2 (fr) 2002-01-16
WO2000057837A9 (fr) 2001-10-18
JP2002540127A (ja) 2002-11-26
AU776684B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
KR100887164B1 (ko) Ｌｉｐｇ 폴리펩타이드의 활성을 증가시키고 초저밀도 지단백질(ｖｌｄｌ) 콜레스테롤 및 저밀도 지단백질(ｌｄｌ) 콜레스테롤의 수준을 저하시키는 조성물 및 이를 위해 유용한 화합물을 동정하는 방법
US7008776B1 (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
JP5416053B2 (ja) トリアシルグリセロールリパーゼファミリーのｌｌｇポリペプチド、組成物、酵素的加水分解における使用のための方法、タンパク質及び遺伝子治療
WO1998024888A9 (fr) Polypeptides llg de la famille des triacylglycerol lipases, compositions et procedes destines a l'utilisation de ceux-ci dans des hydrolyses enzymatiques, et therapies geniques et protidiques

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
N231 Notification of change of applicant
J201 Request for trial against refusal decision
AMND Amendment
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2007101007776; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070716

Effective date: 20071224

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070716

Effective date: 20071224